Apply for Funding

Investment Opportunities | Investment Process |


|Investment Opportunities

Screening Platform

Current Open RFP

GHIT Fund RFP Screening Platform 2017-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

September 1, 2017

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2017-002 Contact Form"

Full Proposal Due

Submit GHIT RFP Screening Platform 2017-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2017-002

Award Notification to All Applicants

To be announced to awarded applicants

Past RFP

GHIT Fund RFP Screening Platform 2017-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

April 1, 2017

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2017-001 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Platform 2017-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2017-001

Award Notification to All Applicants

To be announced to awarded applicants

GHIT Fund RFP Screening Platform 2016-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2016-002 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Plartform 2016-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2016-002

Award Notification to All Applicants

To be announced to awarded applicants

GHIT Fund RFP Screening Platform 2016-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

March 11, 2016

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2016-001 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Plartform 2016-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2016-001

Award Notification to All Applicants

To be announced to awarded applicants

GHIT Fund RFP Screening Platform 2015-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

September 1, 2015

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2015-002 Contact Form

Full Proposal Due

Submit GHIT RFP Screening Plartform 2015-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2015-002

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2015-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

March 25, 2015

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2015-001 Contact Form".

Full Proposal Due

Submit GHIT RFP Screening Plartform 2015-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2015-001

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2014-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

September 1, 2014

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2014-002 Contact Form".

Full Proposal Due

Submit GHIT RFP Screening Plartform 2014-002 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2014-002

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2014-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. 

 

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

 

Possible collaborations should include one of the following three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

 

GHIT Fund staff will contact interested parties to discuss the process of creating partnerships as well as funding. 


RFP and Intent to Apply

Key RFP Milestone Dates

RFP Release

May 22, 2014

Intent to Apply

N/A

Q&A

Questions specific to this Screening Platform can only be answered with the submission of the "GHIT RFP Screening Platform 2014-001 Contact Form".

Full Proposal Due

Submit GHIT RFP Screening Plartform 2014-001 Contact Form to RFPResponse@ghitfund.org

Email Subject Line: Potential Screening Platform 2014-001

Award Notification to All Applicants

To be announced to awarded applicants.

GHIT Fund RFP Screening Platform 2013-002

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions.

The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs.

Possible collaborations should include three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).

Interested partnerships are required to submit the Contact Form by email to RFPResponse@ghitfund.org no later than 5:00pm JST on January 31th, 2014 (please use email subject: Potential Screening Platform 2013-002). Questions specific to this Screening Platform can only be answered with the submission of this information.

A GHIT Fund staff member will contact interested parties to discuss the funding process. If partnerships have not been identified, GHIT Fund staff are available to help facilitate communication with prospective parties. Interested organizations that are not able to form a partnership by the above deadline will be encouraged to participate in future funding calls.


RFP and Intent to Apply

GHIT Fund RFP Screening Platform 2013-001

The GHIT Fund established a Drug Discovery Screening Platform in early 2013 to facilitate the screening of compound libraries for identification of novel compounds for malaria, tuberculosis, Chagas disease and leishmaniasis. The goal is to leverage the active screening programs of established Product Development Partnerships (PDPs) and the relevant compound libraries from Japanese companies or academic institutions. The expectation is that the Japanese entity will provide its relevant compound libraries to their PDP partner, who will then conduct screening with support from their established screening organization network. The GHIT Fund will reimburse for screening project costs. Possible collaborations should include three leading drug development PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB).


RFP and Intent to Apply

RFP Schedule

GHIT Fund RFP Schedule of Screening Platform

2018-001

RFP ReleaseApr, 2018

|Investment Process

process1

Applicants

Contact Form Submission

Interested applicants must complete the Contact Form and submit this to submit by email to RFPResponse@ghitfund.org

process2

Management Team

Eligibility Assessment

For all applications received for the Screening Platform, the GHIT Management Team will conduct eligibility assessments with a focus on partnerships, scope of disease, intervention, and development stage.

process3

Applicants

Discussion with PDPs on project scope

All applications should be submitted as a collaboration between a Japanese organization and one of the following three PDPs: Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases Initiative (DNDi), and the Global Alliance for TB Drug Development (GATB). The details of screening activities will be discussed with representatives from each partner.

process4

Board of Directors

Review

Each screening plan will be reviewed by Board Member.

process5

Japanese organization-PDP-GHIT

Agreement

For approved projects, a three-way agreement (Japanese organization – PDP – GHIT) will be contracted, followed by the initiation of screening activities.

process6

Management Team

Initiation of Monitoring and Evaluation

Once the agreement enters into effect, the GHIT Management Team will initiate the Monitoring and Evaluation process. The data and information regarding the project will be put into the system.

process7

Management Team and Product Development Partners

Monitoring and Evaluation

To track the progress of each project, GHIT conducts progress updates twice a year. This enables us to keep track of the progress of investments and decide whether to continue, modify, or terminate the investment contingent upon milestone achievement. With this system, data pertaining to the progress of each project is gathered via an electronic system and the GHIT Management Team holds a conference with all product development partners based on the collected data prior to the meeting.